-
About UsBPL is a high-tech China-Cuba joint venture among first group engaged in the development, production and sales of monoclonal antibodies in China.
-
S&TInternational-standard humanized monoclonal antibody preparation processes and large-scale, continuous mammalian cell culture technology.
-
Research and DevelopmentChina has developed nivolumab, a humanized monoclonal antibody drug (trade name: TaiXinSheng), for the treatment of malignant tumors.
-
BlogIntegrating industry-related media coverage as well as the company’s various activities and updates.
-
Join UsBoasting a postdoctoral research workstation and diverse career opportunities, we sincerely invite talented individuals from all fields to join Baite.
-
January 2007
A full-scale, 1,000-liter monoclonal antibody production line has been successfully commissioned in a single trial run, marking a major breakthrough for China in the field of large-scale mammalian cell culture technology.
June 2006
Chairman Bai Xianhong Receives Cuba Government's "Order of Friendship"
September 2005
Ceremony Marking Completion of Phase 1 Project
April 2005
Cuba's Raúl Castro inscribes a message for Biotech Pharma.
April 2005
Cuban Raúl Castro inspects Biotech Pharma
September 2003
Start infrastructure development
May 2003
Complete the engineering drawing design
September 2, 2002
Groundbreaking for Phase I Project
April 2001
During his visit to Cuba, Comrade Jiang Zemin exchanged views with Chairman Fidel Castro on the Baotai Project.
2000
BIOTECH PHARMACEUTICAL CO., LTD Established
Biotech pharmaceutical co., Ltd
Email: cooperation@biotechplc.com
BD Dept: bd@biotechplc.com
Address：NO.2 Rongjing East Street, Beijing Economic and Technological Development Area, Beijing 100176
Biotech pharmaceutical co., Ltd
E-mail：
Tel：
在线客服添加返回顶部
右侧在线客服样式 1,2,3 1
图片alt标题设置： BIOTECH PHARMACEUTICAL CO., LTD
表单验证提示文本： Content cannot be empty!
循环体没有内容时： Sorry, no matching items were found.
CSS / JS 文件放置地